<DOC>
	<DOCNO>NCT00000966</DOCNO>
	<brief_summary>To evaluate effectiveness toxicity oral azithromycin pyrimethamine acute therapy toxoplasmic encephalitis AIDS patient . To assess toxicity effectiveness azithromycin alone maintenance therapy . Encephalitis cause Toxoplasma gondii frequent cause focal central nervous system infection patient AIDS . Untreated , encephalitis fatal . Standard treatment toxoplasmic encephalitis associate serious adverse effect . Thus , alternative treatment need .</brief_summary>
	<brief_title>A Study Azithromycin Plus Pyrimethamine Treatment Brain Infection Patients With AIDS</brief_title>
	<detailed_description>Encephalitis cause Toxoplasma gondii frequent cause focal central nervous system infection patient AIDS . Untreated , encephalitis fatal . Standard treatment toxoplasmic encephalitis associate serious adverse effect . Thus , alternative treatment need . Patients toxoplasmosis give azithromycin dos start low dose first cohort , intermediate dose second cohort , high dose third cohort . Subsequent cohort may receive azithromycin increase dosage , need determine MTD . All patient also receive pyrimethamine . Folinic acid also provide long patient receive pyrimethamine . Patients evaluate clinical response treatment day 3 , 7 , 14 , weekly 6 week . Maintenance treatment azithromycin continue additional 24 week . Patients complete study period without relapse significant toxicity offer continued therapy drug company follow survival relapse monthly basis 1 year . After MTD determine , subsequent cohort may add special study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Toxoplasmosis</mesh_term>
	<mesh_term>Toxoplasmosis , Cerebral</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine prophylaxis Pneumocystis carinii pneumonia ( PCP ) . Allowed maintenance period ( week 7 24 ) : Zidovudine antiretrovirals available treatment IND mechanism , ganciclovir , maintenance dos amphotericin ( investigational therapy require permission study chair ) , steroids treatment acute PCP . Isoniazid ( INH ) patient already INH . Patients must follow : HIV infection belong highrisk group . Presumptive definite diagnosis toxoplasmic encephalitis . Each patient , his/her appropriate family member , legal designee must able understand sign write informed consent , accordance local practice site . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : History cerebral toxoplasmosis toxoplasmosis infection organ tissue . Coma . More 72 hour treatment current episode toxoplasmic encephalitis prior study entry . Central nervous system ( CNS ) lymphoma . Cerebral Kaposi 's sarcoma . Active hepatitis clinical jaundice . History serious hypersensitivity intolerance study drug . Serum cerebrospinal fluid ( CSF ) positive cryptococcus antigen culture . Malignancies require use cytotoxic chemotherapy . Inability take oral therapy reliably . Malabsorption syndrome . Concurrent Medication : Excluded : Opportunistic infection require either acute treatment maintenance therapy azithromycin , erythromycin macrolides , sulfonamide , amphotericin , dapsone , ganciclovir , antifolates , investigational agent except erythropoietin . For first 6 week treatment , patient may receive treatment erythromycin ( macrolides ) , sulfonamide , immunomodulators exception alpha interferon , lymphocyte replacement , cytotoxic chemotherapy , dapsone , ganciclovir , rifampicin , coumadin , antiretrovirals , investigational agent erythropoietin . Patients follow excluded : Negative HIV antibody federally license ELISA , unless documentation previously positive HIV culture p24 antigen . Infections central nervous system . Malignancies require use cytotoxic chemotherapy . Any medical social condition , opinion investigator , would adversely affect participation and/or compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1994</verification_date>
	<keyword>Toxoplasmosis</keyword>
	<keyword>Toxoplasma</keyword>
	<keyword>Pyrimethamine</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Azithromycin</keyword>
</DOC>